A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF REVN24 IN HEALTHY MALE VOLUNTEERS
Latest Information Update: 02 Dec 2025
At a glance
- Drugs REVN 24 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 02 Dec 2025 New trial record